Perfluorodecanoic acid
Based on 1 publication(s) in Google Scholar
Perfluorodecanoic acid (PFDA) is an orally active perfluoroalkyl substance. Perfluorodecanoic acid causes dysfunction of rat fetal Leydig cells via endoplasmic reticulum stress-mediated changes in lipid components. Perfluorodecanoic acid reduces testosterone biosynthesis in rat R2C Leydig cells by inducing endoplasmic reticulum stress. Perfluorodecanoic acid can be used in studies related to fetal Leydig cell dysfunction.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 335-76-2
- Formule: C10HF19O2
- Masse moléculaire:514.08
-
Stockage:
Store at room temperature, keep dry and cool.
In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Differentiation Inducing Compound Library
HY-L038
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Angiogenesis-Related Compound Library
HY-L088
-
Protease Inhibitor Library
HY-L147
-
Cytokine Inhibitors Library
HY-L161
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Perfluorodecanoic acid
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
|
Caspase-1 |
Caspase 3 |
Caspase-7 |
IL-1β |
Perfluorodecanoic acid (0-150 μM; 24 h) reduces testosterone biosynthesis in rat R2C Leydig cells by inducing endoplasmic reticulum stress, in which 100 μM PFDA (24 h incubation) significantly inhibits steroidogenesis, while 150 μM PFDA (24 h incubation) decreases cell viability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:rat R2C Leydig cells
-
Concentration:50-150 μM (cell viability assay); 100 μM (testosterone biosynthesis assay)
-
Incubation Time:24 h (cell viability assay); 24 h (testosterone biosynthesis assay)
-
Result:Showed negligible impact on cell viability at concentrations up to 125 μM for 24 h.
Significantly reduced cell viability at 150 μM for 24 h.
Significantly decreased testosterone synthesis at 100 μM for 24 h.
Downregulated mRNA levels of steroidogenesis-related genes at 100 μM for 24 h.
Increased phosphorylation levels of ER stress proteins PERK and EIF2α at 100 μM for 24 h.
Reduced protein levels of steroidogenesis-related proteins including SCARB1, STAR, CYP11A1, and HSD3B1 at 100 μM for 24 h.
Perfluorodecanoic acid (PFDA) (0.03-32.0 mg/kg/day; p.o. [gavage]; daily; 4 consecutive days on gd 6-15) induces maternal toxicity (decreased body weight gain, increased liver weight) and embryonic toxicity (decreased live fetal body weight, non-significant increase in embryonic mortality at the highest dose, rare mild external malformations) in time-mated C57BL/6N mice dosed on gd 6-15, with no teratogenic effects observed[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (56 days old; male and female dams; male neonatal pups; in utero exposure via gestational dam treatment from gestational day 14 to 21)[1]
-
Dosage:1 mg/kg/day; 2.5 mg/kg/day; 5 mg/kg/day
-
Administration:p.o.; daily; gestational day 14 to 21
-
Result:Increased male pup body weight at 1 and 2.5 mg/kg/day; decreased male pup body weight at 5 mg/kg/day.
Decreased anogenital distance at all doses.
Significantly reduced serum testosterone levels at 2.5 and 5 mg/kg/day.
Downregulated mRNA and protein levels of fetal Leydig cell genes/proteins including Lhcgr, Scarb1, Star, Cyp11a1, Hsd3b1, Cyp17a1, Insl3, and Gli1 at all doses.
Reduced fetal Leydig cell size and cytoplasmic size at all doses.
Induced multinucleated gonocyte formation in testicular cords at 2.5 and 5 mg/kg/day.
Upregulated Elovl1 mRNA and downregulated Scd2 mRNA at 5 mg/kg/day.
Increased phosphorylation of PERK and EIF2α at all doses.
Increased ATF4 protein levels at all doses; increased ATF6 and GRP78 protein levels at 2.5 and 5 mg/kg/day.
Reduced SCARB1 protein levels; increased ELOVL1 protein levels; reduced SCD2 protein levels at all doses.
-
Animal Model:C57BL/6N (female, 6-8 weeks of age, time-mated, gestation day 0 defined by vaginal plug observation)[3]
-
Dosage:0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0 mg/kg/day
-
Administration:p.o. [gavage]; daily; 4 consecutive days on gd 10-13
-
Result:Significantly reduced maternal body weight gain.
Significantly increased absolute maternal liver weights .
Significantly increased relative maternal liver weights.
Significantly reduced live fetal body weigh.
Observed non-significant increase in fetal mortality.
Observed rare minor fetal external variations: 1 fetus with left neck hematoma.
Detected no hydronephrosis, cleft palate, or other soft tissue or skeletal malformations at any dose.
Chemical Information
-
CAS No. 335-76-2
-
Appearance Solid
-
Masse moléculaire 514.08
-
Formule C10HF19O2
-
Color White to off-white
-
SMILES
C(=O)(C(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)O
-
Synonyms
PFDA
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Store at room temperature, keep dry and cool
In solvent -80°C 1 year -20°C 6 months
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Chem Res Toxicol
In Utero Perfluorodecanoic Acid Exposure Causes Fetal Leydig Cell Dysfunction via Endoplasmic Reticulum Stress-Mediated Lipid Composition Alteration. [Abstract]2025 Feb 17;38(2):314-324. PMID: 39814558
Solvant et solubilité
Ethanol : 100 mg/mL (194.52 mM; Need ultrasonic)
DMSO : ≥ 100 mg/mL (194.52 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ren Z, et al. In Utero Perfluorodecanoic Acid Exposure Causes Fetal Leydig Cell Dysfunction via Endoplasmic Reticulum Stress-Mediated Lipid Composition Alteration. Chem Res Toxicol. 2025;38(2):314-324. [Content Brief]
[2]. Olson CT, et al. The acute toxicity of perfluorooctanoic and perfluorodecanoic acids in male rats and effects on tissue fatty acids. Toxicol Appl Pharmacol. 1983;70(3):362-372. [Content Brief]
[3]. Harris MW, et al. Developmental toxicity of perfluorodecanoic acid in C57BL/6N mice. Fundam Appl Toxicol. 1989;12(3):442-448. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 1.9452 mL | 9.7261 mL | 19.4522 mL | 48.6306 mL |
| 5 mM | 0.3890 mL | 1.9452 mL | 3.8904 mL | 9.7261 mL | |
| 10 mM | 0.1945 mL | 0.9726 mL | 1.9452 mL | 4.8631 mL | |
| 15 mM | 0.1297 mL | 0.6484 mL | 1.2968 mL | 3.2420 mL | |
| 20 mM | 0.0973 mL | 0.4863 mL | 0.9726 mL | 2.4315 mL | |
| 25 mM | 0.0778 mL | 0.3890 mL | 0.7781 mL | 1.9452 mL | |
| 30 mM | 0.0648 mL | 0.3242 mL | 0.6484 mL | 1.6210 mL | |
| 40 mM | 0.0486 mL | 0.2432 mL | 0.4863 mL | 1.2158 mL | |
| 50 mM | 0.0389 mL | 0.1945 mL | 0.3890 mL | 0.9726 mL | |
| 60 mM | 0.0324 mL | 0.1621 mL | 0.3242 mL | 0.8105 mL | |
| 80 mM | 0.0243 mL | 0.1216 mL | 0.2432 mL | 0.6079 mL | |
| 100 mM | 0.0195 mL | 0.0973 mL | 0.1945 mL | 0.4863 mL |
Perfluorodecanoic acid Related Classifications
HY-W269593 Related Classifications
Powered by Bioz